SPS
PHAT icon

Susquehanna Portfolio Strategies’s Phathom Pharmaceuticals PHAT Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.98M Hold
267,962
– – 0.04% 402
2025
Q4 		$4.45M Hold
267,962
– – 0.07% 326
2025
Q3 		$3.15M Hold
267,962
– – 0.05% 405
2025
Q2 		$2.57M Buy
+267,962
New +$1.48M 0.06% 323

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Susquehanna Portfolio Strategies's PHAT Position: Q1 2026 in Review

Susquehanna Portfolio Strategies held its Phathom Pharmaceuticals (PHAT) position steady in Q1 2026 at 267,962 shares worth $2.98M. The position accounts for 0.04% of the portfolio, ranked #402.

Susquehanna Portfolio Strategies first reported a position in PHAT in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.45M in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Susquehanna Portfolio Strategies held 267,962 shares of Phathom Pharmaceuticals worth $2.98M as of Q1 2026.
  • Susquehanna Portfolio Strategies left its Phathom Pharmaceuticals share count unchanged in Q1 2026.
  • Phathom Pharmaceuticals made up 0.04% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #402 holding.
  • Susquehanna Portfolio Strategies first reported a position in Phathom Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Susquehanna Portfolio Strategies's Phathom Pharmaceuticals position peaked at $4.45M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.